ClinicalTrials.gg
Active, not recruitingNCT07071714Updated Aug 11, 2026

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

A Phase 2 interventional study of SHR-8068 Injection and Adebrelimab Injection in Colorectal Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 2 open to participants now, 5 under way, 3 of them phase 3. Colorectal Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
6th of 11
103 · median 103
Started
2025
the only one that year
Phase 2
5 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 5 in phase 2, and was the 9th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form.
  2. Male or female ≥ 18 years old and ≤75 years old.
  3. performance status of 0-1.
  4. Part A with a of ≥2 years. Part B with a life expectancy of ≥12 weeks.
  5. Need to provided tumor tissue samples for genetic testing.

Exclusion criteria

Exclusion Criteria:

  1. Part B: Accompanied by untreated or active central nervous system (CNS) . Subjects with a history or current history of meningeal metastasis.
  2. Part B: Systemic antitumor therapy was received 4 weeks before the start of the study.
  3. Part B: Palliative radiotherapy was completed within 14 days before the first dose.
  4. Toxicity and/or complications from previous interventions did not return to level ≤1 or exclusion criteria.
  5. Subjects with known or suspected interstitial pneumonia.
  6. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion.
  7. Have poorly controlled or severe cardiovascular disease.
  8. Subjects with active or active .
  9. A history of immunodeficiency, including a positive test, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.
  10. The presence of uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention.
  11. Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Part A Group

    Drug: SHR-8068 Injection · Drug: Adebrelimab Injection

  • Experimental
    Part B Group

    Drug: SHR-8068 Injection · Drug: Adebrelimab Injection · Drug: Bevacizumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR)

    Time frame: About 7 months.

  2. Progression Free Survival (PFS)

    Time frame: About 18 months.

Secondary outcomes

  1. Clinical Complete Response (cCR)

    Time frame: About 60 months.

  2. Disease Free Survival (DFS)

    Time frame: About 60 months.

  3. Event Free Survival (EFS)

    Time frame: About 60 months.

  4. Overall Survival (OS)

    Time frame: About 60 months.

  5. Duration of Response (DoR)

    Time frame: About 18 months.

  6. Overall Response Rate (ORR)

    Time frame: About 18 months.

  7. Disease Control Rate (DCR)

    Time frame: About 18 months.

  8. Adverse Events (AEs)

    Time frame: Up to about 18 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2031, 75 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 75 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Oct 2031
CompletionEst.
Oct 2031
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071714
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Jul 22, 2025
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Aug 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CTLA-4 Monoclonal Antibody SHR-8068

Start the discussion